X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Apabetalone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVX-208
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
In BETonMACE study, significantly fewer hospitalizations for heart failure (HHF) in patients with type 2 diabetes and a recent history of acute coronary syndrome (ACS) were observed in the apabetalone treatment group compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies and Piper Sandler
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 23, 2020
Details:
Milestone intends to use the net proceeds from the offering primarily to fund the clinical development of its lead product candidate etripamil, and for general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Omega-3 phospholipid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Capre
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Omega-3 phospholipid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Capre
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
Analysis of the TRILOGY 1 data revealed a rapid, significant and sustained reduction in Triglyceride levels between screening and the time of patient randomization, which Acasti refers to as “Pre-randomization Triglyceride Normalization.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
